Andrea Charles | 09/13/2011
Professor René Bernards, Head of the Division/Group Leader, Molecular Carcinogenesis at The Netherlands Cancer Institute, joins Andrea Charles from Pharma IQ, to discuss current trends in next-generation DNA sequencing in oncology research, industry uptake of next-generation DNA sequencing technologies, the advantages of enriching and true commercial potential of personalised medicine. Have Your Say Rate this feature and give us your feedback in the comments section below
To continue reading this story Click Here
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More